Consistency in the performance of CDRH review divisions has improved in recent years, but FDA and lawmakers should closely monitor uniformity across the center and consider the need for reforms, according to the California Healthcare Institute.
CHI, an advocate for California’s biomedical companies, issued a report with help from The Boston Consulting Group on Oct. 23 assessing FDA's device review performance. It is based...